Hemali Shah

Hemali Shah


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2024 in American Journal of Clinical Dermatology
Verified
Journal Article
Open access
PDF file
HSHemali Shah
Hemali Shah
Rose ParisiRose Parisi
Rose Parisi
EMEric Mukherjee
Eric Mukherjee
EPElizabeth J. Phillips
Elizabeth J. Phillips
RDRoni P. Dodiuk-Gad
Roni P. Dodiuk-Gad
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are the most severe cutaneous adverse reactions that are typically drug-induced in adults. Both SJS and TEN have high morbidity and mortality rates. SJS/TEN imposes clinical challenges for physicians managing patients suffering from this condition, both because it is rare and because it is a rapidly progressing systemic disease with severe cutaneous, mucosal, and systemic manifestations. Although many cases of SJS/TEN have been reported in the literature, there is no consensus regarding diagnostic criteria or treatment. Significant progress has been made in understanding its genetic predisposition and pathogenesis. This review is intended to provide physicians with a comprehensive but practical SJS/TEN roadmap to guide diagnosis and management. We review data on pathogenesis, reported precipitating factors, presentation, diagnosis, and management SJS/TEN focusing on what is new over the last 5 years.

8 May 2023 in American Journal of Clinical Dermatology
Verified
Journal Article
Closed access
PDF file
Rose ParisiRose Parisi
Rose Parisi
HSHemali Shah
Hemali Shah
Alexander NavariniAlexander Navarini
Alexander Navarini
BMBeda Muehleisen
Beda Muehleisen
MZMichael Ziv
Michael Ziv
RDRoni P. Dodiuk-Gad
Roni P. Dodiuk-Gad

20 July 2018 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
VMVishnu P. Murty
Vishnu P. Murty
HSHemali Shah
Hemali Shah
DMDavid Montez
David Montez
WFWill Foran
Will Foran
FCFinnegan Calabro
Finnegan Calabro
BLBeatriz Luna
Beatriz Luna
Over-engagement of the mesolimbic dopamine system is thought to enhance motivation in adolescents. Whereas human neuroimaging has characterized event-evoked responses of the mesolimbic system in adolescents, research has yet to characterize state-dependent engagement (i.e., seconds to minutes) of this system in goal-relevant contexts. In the current longitudinal study, we characterized age-related changes in state-dependent coupling in male and female human participants ranging in age from adolescence to adulthood. Analyses focused on two key regions of the mesolimbic dopamine system, the ventral tegmental area (VTA) and nucleus accumbens (NAcc). Although there were no differences in VTA–NAcc functional coupling in a resting-state context, VTA–NAcc functional coupling was enhanced in preadolescence/early adolescence and decreased into adulthood in a motivational context, in which individuals had to translate goal-relevant cues into instrumental actions. Furthermore, we found that task-related activation in orbitofrontal cortex, middle temporal gyrus, and visual association cortex partially mediated age-related changes in state-dependent VTA–NAcc functional coupling. These results extend prior models of neurodevelopment by showing a relationship between cortical event-evoked activation and state-dependent increases in subcortical engagement of mesolimbic systems. SIGNIFICANCE STATEMENT Adolescence is characterized by increased motivated behavior, which is thought to result from an over-engagement of mesolimbic dopamine systems. Rodent models show increases in state-dependent engagement of mesolimbic systems in adolescence. However, human neuroimaging research has mainly focused on event-evoked responses (i.e., reward cues). We show that in motivational contexts, there is increased state-dependent coupling across mesolimbic systems in preadolescence/early adolescence that decreases into adulthood and is further predicted by event-evoked cortical responses. Critically, these developmental trajectories were specific to motivationally relevant contexts and were not apparent during resting state. These findings extend emerging models of human development and suggest that state-dependent increases in dopamine signaling may underlie heightened motivation.

16 June 2022 in Cureus
Verified
Journal Article
Open access
HSHemali Shah
Hemali Shah
ABAna C. Busquets
Ana C. Busquets
Much of the literature involving COVID-19 and chronic inflammatory dermatological conditions have focused on the safety of immunomodulatory therapy in the setting of this highly infectious virus. While general mortality associated with the infection and vaccine has been studied in depth, the effects of the virus and vaccine on inflammatory skin disease states have not been. It is well known that psoriasis can be triggered by stress, infection, certain medications, and, although not as common, vaccinations. Further, existing literature has briefly commented on psoriasis flares after COVID vaccination, but these have not touched on flares among their patients’ current therapy, nor flares after COVID infection. In this case report, we report five cases observed at our institution over the last year of either new-onset psoriasis or flares of previously well-controlled psoriasis shortly after infection with COVID-19 or COVID-19 vaccination, with no other identifiable triggers. These cases can serve to raise awareness of issues related to managing stubborn psoriatic flares and bring to the forefront conversations that are likely to arise with our patients regarding the risks and benefits of COVID vaccination and boosters. While the definitive etiology of the association between COVID and psoriasis remains unclear, it is important that the dermatologic community be aware when evaluating patients with new-onset or worsening psoriasis as we move forward in times of this COVID-19 era.

24 January 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Rose ParisiRose Parisi
Rose Parisi
HSHemali Shah
Hemali Shah
NSNeil H. Shear
Neil H. Shear
MZMichael Ziv
Michael Ziv
AMAlina Markova
Alina Markova
RDRoni P. Dodiuk-Gad
Roni P. Dodiuk-Gad
The rapid evolution of anti-cancer therapy (including chemotherapy, targeted therapy, and immunotherapy) in recent years has led to a more favorable efficacy and safety profile for a growing cancer population, and the improvement of overall survival and reduction of morbidity for many cancers. Anti-cancer therapy improves outcomes for cancer patients; however, many classes of anti-cancer therapy have been implicated in the induction of bullous dermatologic adverse events (DAE), leading to reduced patient quality of life and in some cases discontinuation of life-prolonging or palliative therapy. Timely and effective management of adverse events is critical for reducing treatment interruptions and preserving an anti-tumor effect. Bullous DAE may be limited to the skin or have systemic involvement with greater risk of morbidity and mortality. We present the epidemiology, diagnosis, pathogenesis, and management of bullous DAE secondary to anti-cancer therapies to enable clinicians to optimize management for these patients.

31 May 2023 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
DEDaphne G. Eckembrecher
Daphne G. Eckembrecher
FEFrancelia J. Eckembrecher
Francelia J. Eckembrecher
ICIsabella Camacho
Isabella Camacho
HSHemali Shah
Hemali Shah
YDYogi Dave
Yogi Dave
KNKeyvan Nouri
Keyvan Nouri